Oriana Lo Re

Dr. Oriana Lo Re

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
OROriana Lo Re
Oriana Lo Re
CFCaterina Fusilli
Caterina Fusilli
FRFrancesca Rappa
Francesca Rappa
MHMatthias Van Haele
Matthias Van Haele
JDJulien Douet
Julien Douet
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra

20 September 2016 in Epigenetics
Verified
Journal Article
Open access
SJSimone Jueliger
Simone Jueliger
JLJohn Lyons
John Lyons
SCSARA CANNITO
SARA CANNITO
IPIllar Pata
Illar Pata
PPPille Pata
Pille Pata
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-generation hypomethylating agent, which inhibits DNA methyltransferases. Guadecitabine is formulated as a dinucleotide of decitabine and deoxyguanosine that is resistant to cytidine deaminase (CDA) degradation and results in prolonged in vivo exposure to decitabine following small volume subcutaneous administration of guadecitabine. Here we found that guadecitabine is an effective demethylating agent and is able to prevent HCC progression in pre-clinical models. In a xenograft HCC HepG2 model, guadecitabine impeded tumor growth and inhibited angiogenesis, while it could not prevent liver fibrosis and inflammation in a mouse model of steatohepatitis. Demethylating efficacy of guadecitabine on LINE-1 elements was found to be the highest 8 d post-infusion in blood samples of mice. Analysis of a panel of human HCC vs. normal tissue revealed a signature of hypermethylated tumor suppressor genes (CDKN1A, CDKN2A, DLEC1, E2F1, GSTP1, OPCML, E2F1, RASSF1, RUNX3, and SOCS1) as detected by methylation-specific PCR. A pronounced demethylating effect of guadecitabine was obtained also in the promoters of a subset of tumor suppressors genes (CDKN2A, DLEC1, and RUNX3) in HepG2 and Huh-7 HCC cells. Finally, we analyzed the role of macroH2A1, a variant of histone H2A, an oncogene upregulated in human cirrhosis/HCC that synergizes with DNA methylation in suppressing tumor suppressor genes, and it prevents the inhibition of cell growth triggered by decitabine in HCC cells. Guadecitabine, in contrast to decitabine, blocked growth in HCC cells overexpressing macroH2A1 histones and with high CDA levels, despite being unable to fully demethylate CDKN2A, RUNX3, and DLEC1 promoters altered by macroH2A1. Collectively, our findings in human and mice models reveal novel epigenetic anti-HCC effects of guadecitabine, which might be effective specifically in advanced states of the disease.

22 June 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
JPJana Pindjakova
Jana Pindjakova
CSClaudio Sartini
Claudio Sartini
OROriana Lo Re
Oriana Lo Re
FRFrancesca Rappa
Francesca Rappa
BCBerengere Coupe
Berengere Coupe
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra
A mutual interplay exists between adaptive immune system and gut microbiota. Altered gut microbial ecosystems are associated with the metabolic syndrome, occurring in most obese individuals. However, it is unknown why 10-25% of obese individuals are metabolically healthy, while normal weight individuals can develop inflammation and atherosclerosis. We modelled these specific metabolic conditions in mice fed with a chow diet, an obesogenic but not inflammatory diet - mimicking healthy obesity, or Paigen diet - mimicking inflammation in the lean subjects. We analysed a range of markers and cytokines in the aorta, heart, abdominal fat, liver and spleen, and metagenomics analyses were performed on stool samples. T lymphocytes infiltration was found in the aorta and in the liver upon both diets, however a significant increase in CD4+ and CD8+ cells was found only in the heart of Paigen-fed animals, paralleled by increased expression of IL-1, IL-4, IL-6, IL-17 and IFN-gamma. Bacteroidia, Deltaproteobacteria and Verrucomicrobia dominated in mice fed Paigen diet, while Gammaproteobacteria, Delataproteobacteria and Erysipelotrichia were more abundant in obese mice. Mice reproducing human metabolic exceptions displayed gut microbiota phylogenetically distinct from normal diet-fed mice, and correlated with specific adaptive immune responses. Diet composition thus has a pervasive role in co-regulating adaptive immunity and the diversity of microbiota.

4 May 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
OROriana Lo Re
Oriana Lo Re
CPConcetta Panebianco
Concetta Panebianco
SPStefania Porto
Stefania Porto
CCCarlo Cervi
Carlo Cervi
FRFrancesca Rappa
Francesca Rappa
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra

3 August 2018 in Epigenetics
Verified
Journal Article
Closed access
OROriana Lo Re
Oriana Lo Re
JDJulien Douet
Julien Douet
MBMarcus Buschbeck
Marcus Buschbeck
CFCaterina Fusilli
Caterina Fusilli
Valerio PazienzaValerio Pazienza
Valerio Pazienza
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra
Hepatocellular carcinomas (HCCs) contain a sub-population of cancer stem cells (CSCs) that are responsible for tumor relapse, metastasis, and chemoresistance. We recently showed that loss of macroH2A1, a variant of the histone H2A and an epigenetic regulator of stem-cell function, in HCC leads to CSC-like features such as resistance to chemotherapeutic agents and growth of large and relatively undifferentiated tumors in xenograft models. These HCC cells silenced for macroH2A1 also exhibited stem-like metabolic changes consistent with enhanced glycolysis. However, there is no consensus as to the metabolic characteristics of CSCs that render them adaptable to microenvironmental changes by conveniently shifting energy production source or by acquiring intermediate metabolic phenotypes. Here, we assessed long-term proliferation, energy metabolism, and central carbon metabolism in human hepatoma HepG2 cells depleted in macroH2A1. MacroH2A1-depleted HepG2 cells were insensitive to serum exhaustion and showed two distinct, but interdependent changes in glucose and lipid metabolism in CSCs: (1) massive upregulation of acetyl-coA that is transformed into enhanced lipid content and (2) increased activation of the pentose phosphate pathway, diverting glycolytic intermediates to provide precursors for nucleotide synthesis. Integration of metabolomic analyses with RNA-Seq data revealed a critical role for the Liver X Receptor pathway, whose inhibition resulted in attenuated CSCs-like features. These findings shed light on the metabolic phenotype of epigenetically modified CSC-like hepatic cells, and highlight a potential approach for selective therapeutic targeting.

1 January 2020 in Theranostics
Verified
Journal Article
Open access
OROriana Lo Re
Oriana Lo Re
Tommaso MazzaTommaso Mazza
Tommaso Mazza
SGSebastiano Giallongo
Sebastiano Giallongo
PSPaola Sanna
Paola Sanna
FRFrancesca Rappa
Francesca Rappa
Manlio VinciguerraManlio Vinciguerra
Manlio Vinciguerra
Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear.